144 related articles for article (PubMed ID: 304143)
1. Transference of cell mediated immunity in patients with head and neck cancer.
Vetto RM; Burger DR
Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):79-82. PubMed ID: 304143
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy.
Olkowski ZL; McLaren JR; Skeen MJ
Cancer Treat Rep; 1978 Nov; 62(11):1651-61. PubMed ID: 310339
[TBL] [Abstract][Full Text] [Related]
3. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.
Kerrebijn JD; Simons PJ; Balm AJ; Tas M; Knegt PP; de Vries N; Tan IB; Drexhage HA
Head Neck; 1996; 18(4):335-42. PubMed ID: 8780944
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the mechanism of the leukocyte adherence inhibition test.
Tong AW; Burger DR; Finke P; Barney C; Vandenbark AA; Vetto RM
Cancer Res; 1979 Feb; 39(2 Pt 2):597-603. PubMed ID: 367586
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunity in patients with epidermoid cancer of the head and neck.
Papenhausen PR; Kukwa A; Croft CB; Borowiecki B; Silver C; Emeson EE
Laryngoscope; 1979 Apr; 89(4):538-49. PubMed ID: 311881
[TBL] [Abstract][Full Text] [Related]
6. Effect of thymosin and irradiation on immune modulation in head and neck and esophageal cancer patients.
Wara WM; Ammann AJ; Wara DW
Cancer Treat Rep; 1978 Nov; 62(11):1775-8. PubMed ID: 728896
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
8. Preservation of in vitro biological functions in regional lymph node lymphocytes in squamous head and neck cancer.
Saxon A; Portaro J
Cancer Res; 1977 Apr; 37(4):1159-64. PubMed ID: 139203
[TBL] [Abstract][Full Text] [Related]
9. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma.
Wolf GT; Carey TE
J Natl Cancer Inst Monogr; 1992; (13):67-74. PubMed ID: 1389697
[TBL] [Abstract][Full Text] [Related]
11. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
13. An immunological outcome predictive score for head and neck carcinoma patients.
Kaffenberger W; Hölzer-Müller L; Auberger T; Clasen BP; Hohlmeier G; van Beuningen D
Strahlenther Onkol; 1995 Aug; 171(8):444-53. PubMed ID: 7652667
[TBL] [Abstract][Full Text] [Related]
14. Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck.
Verastegui E; Morales R; Barrera JL; Müeller A; Guzman B; Meneses A; Alfaro G
Clin Immunol; 2002 Jan; 102(1):37-47. PubMed ID: 11781066
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.
Pak AS; Wright MA; Matthews JP; Collins SL; Petruzzelli GJ; Young MR
Clin Cancer Res; 1995 Jan; 1(1):95-103. PubMed ID: 9815891
[TBL] [Abstract][Full Text] [Related]
16. The relationship of circulating IgA to cellular immunity in head and neck cancer patients.
Schantz SP; Liu FJ; Taylor D; Beddingfield N; Weber RS
Laryngoscope; 1988 Jun; 98(6 Pt 1):671-8. PubMed ID: 3259661
[TBL] [Abstract][Full Text] [Related]
17. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
18. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
19. A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck.
Deegan MJ; Coulthard SW; Quaiman SJ; Schork MA
Cancer Res; 1977 Dec; 37(12):4475-81. PubMed ID: 144562
[No Abstract] [Full Text] [Related]
20. Immune defects in patients with head and neck cancer.
Wustrow TP; Issing WJ
Anticancer Res; 1993; 13(6B):2507-19. PubMed ID: 8135491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
